OTCMKTS:PPCB

Propanc Biopharma News Headlines

$0.22
-0.01 (-4.35 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.22
Now: $0.22
$0.23
50-Day Range
$0.23
MA: $0.29
$0.45
52-Week Range
$0.20
Now: $0.22
$24.00
Volume18,640 shs
Average Volume141,431 shs
Market Capitalization$1.03 million
P/E RatioN/A
Dividend YieldN/A
Beta1.9

Headlines

Propanc Biopharma (OTCMKTS PPCB) News Headlines Today

SourceHeadline
Short Interest in Propanc Biopharma, Inc. (OTCMKTS:PPCB) Decreases By 60.1%Short Interest in Propanc Biopharma, Inc. (OTCMKTS:PPCB) Decreases By 60.1%
americanbankingnews.com - March 28 at 3:22 PM
Propanc Biopharma Provides Upcoming MilestonesPropanc Biopharma Provides Upcoming Milestones
finance.yahoo.com - March 25 at 12:39 PM
Propanc Biopharma Provides A Shareholder Update for 2021Propanc Biopharma Provides A Shareholder Update for 2021
finance.yahoo.com - March 3 at 12:14 PM
Professor Juan Marchal Believes Propanc Biopharma’s Proenzyme Therapy May Offer New Treatment Opportunity for Cancer PatientsProfessor Juan Marchal Believes Propanc Biopharma’s Proenzyme Therapy May Offer New Treatment Opportunity for Cancer Patients
finance.yahoo.com - February 15 at 9:36 AM
Propanc Biopharma Appoints Belen Toledo to Evaluate Impact of Proenzyme Therapy on Tumor MicroenvironmentPropanc Biopharma Appoints Belen Toledo to Evaluate Impact of Proenzyme Therapy on Tumor Microenvironment
finance.yahoo.com - January 28 at 2:05 PM
Propanc Biopharma, Inc.: Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer PatientsPropanc Biopharma, Inc.: Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients
finanznachrichten.de - January 19 at 7:02 PM
Propanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer PatientsPropanc Biopharma Receives Expression of Interest to Evaluate Proenzyme Therapy in Pancreatic and Ovarian Cancer Patients
finance.yahoo.com - January 19 at 7:02 PM
Propanc Biopharma Analyzes Pancreatic Proenzymes Vs T-Cell Therapy Targeting Solid Tumors Such as Pancreatic, Ovarian & Colorectal CancersPropanc Biopharma Analyzes Pancreatic Proenzymes Vs T-Cell Therapy Targeting Solid Tumors Such as Pancreatic, Ovarian & Colorectal Cancers
finance.yahoo.com - January 11 at 10:15 AM
Propanc Biopharma Advances POP1 Joint Research and Drug Discovery Program for Projected US$111.2B Global Metastatic Cancer MarketPropanc Biopharma Advances POP1 Joint Research and Drug Discovery Program for Projected US$111.2B Global Metastatic Cancer Market
finance.yahoo.com - December 30 at 1:00 PM
Propanc Biopharma Receives First Granted Patent for Method to Treat Cancer Stem Cells from Australian Patent OfficePropanc Biopharma Receives First Granted Patent for Method to Treat Cancer Stem Cells from Australian Patent Office
finance.yahoo.com - December 21 at 9:04 AM
Propanc Biopharma Inc (PPCB)Propanc Biopharma Inc (PPCB)
nasdaq.com - October 20 at 7:20 PM
Propanc Biopharma, Inc. (PPCB)Propanc Biopharma, Inc. (PPCB)
ca.finance.yahoo.com - October 17 at 6:47 PM
Propanc Biopharma Inc.Propanc Biopharma Inc.
marketwatch.com - September 17 at 8:13 PM
Propanc Biopharma Receives Investment from Institutional InvestorPropanc Biopharma Receives Investment from Institutional Investor
finance.yahoo.com - July 28 at 12:46 PM
Propanc Biopharma Provides Shareholder UpdatePropanc Biopharma Provides Shareholder Update
finance.yahoo.com - May 11 at 5:57 PM
How Propanc Biopharma Is Joining the Fight with Cancer Patients Who Are Increasingly Vulnerable to the COVID-19 Global PandemicHow Propanc Biopharma Is Joining the Fight with Cancer Patients Who Are Increasingly Vulnerable to the COVID-19 Global Pandemic
finance.yahoo.com - April 16 at 11:37 AM
Propanc Biopharma Receives First Allowance for Key Patent Family from Australian Patent OfficePropanc Biopharma Receives First Allowance for Key Patent Family from Australian Patent Office
finance.yahoo.com - April 14 at 3:55 PM
Propanc Biopharma Enters Into a $3 Million Financing with Institutional InvestorPropanc Biopharma Enters Into a $3 Million Financing with Institutional Investor
finance.yahoo.com - March 31 at 12:30 PM
Propanc Biopharmas Scientific Advisory Board Member Promoted to Professorship Position at Jaén University, SpainPropanc Biopharma's Scientific Advisory Board Member Promoted to Professorship Position at Jaén University, Spain
www.finanznachrichten.de - March 16 at 9:04 AM
Propanc Biopharma’s Scientific Advisory Board Member Promoted to Professorship Position at Jaén University, SpainPropanc Biopharma’s Scientific Advisory Board Member Promoted to Professorship Position at Jaén University, Spain
finance.yahoo.com - March 16 at 9:04 AM
Propanc Biopharma Receives Advance Overseas Finding from Innovation and Science AustraliaPropanc Biopharma Receives Advance Overseas Finding from Innovation and Science Australia
finance.yahoo.com - January 21 at 4:17 PM
Propanc Biopharma nears production of synthetic pancreatic proenzymesPropanc Biopharma nears production of synthetic pancreatic proenzymes
www.proactiveinvestors.com - November 18 at 5:19 PM
Propanc Biopharma Advances POP1 Drug Discovery ProgramPropanc Biopharma Advances POP1 Drug Discovery Program
finance.yahoo.com - November 18 at 12:18 PM
Propanc Biopharma Provides Shareholder Update and Forecast for 2020Propanc Biopharma Provides Shareholder Update and Forecast for 2020
finance.yahoo.com - October 29 at 9:08 AM
Propanc Biopharma plans to advance clinical trials on lead cancer drug PRPPropanc Biopharma plans to advance clinical trials on lead cancer drug PRP
www.proactiveinvestors.com - October 21 at 1:58 PM
Propanc Biopharma Illustrates Novel Mode of Action of PRP, Suppressing EMT Pathways and Metastasis in Cancer PatientsPropanc Biopharma Illustrates Novel Mode of Action of PRP, Suppressing EMT Pathways and Metastasis in Cancer Patients
finance.yahoo.com - October 21 at 8:58 AM
Propanc Biopharma Receives Granted US Patent Covering Additional Composition Claims for PRPPropanc Biopharma Receives Granted US Patent Covering Additional Composition Claims for PRP
finance.yahoo.com - August 21 at 9:43 AM
Propanc Biopharma Completes Development of Bio-analytical Assay Method to Quantify PRP’s Active Ingredients in Preparation for First-In-Human StudyPropanc Biopharma Completes Development of Bio-analytical Assay Method to Quantify PRP’s Active Ingredients in Preparation for First-In-Human Study
finance.yahoo.com - August 8 at 11:37 AM
Propanc Biopharma Provides Update on Preparation of PRP for Clinical Trial Application Submission and Recently Completed Reverse Stock SplitPropanc Biopharma Provides Update on Preparation of PRP for Clinical Trial Application Submission and Recently Completed Reverse Stock Split
markets.businessinsider.com - July 15 at 10:17 AM
Propanc Biopharma Appoints Carlo Campiciano as Chief Financial OfficerPropanc Biopharma Appoints Carlo Campiciano as Chief Financial Officer
finance.yahoo.com - July 14 at 9:48 AM
Propanc poised to unlock shareholder value as it boosts its patent portfolio for cancer-fighting drugsPropanc poised to unlock shareholder value as it boosts its patent portfolio for cancer-fighting drugs
www.proactiveinvestors.com.au - June 27 at 5:00 PM
Propanc Biopharma appoints Carlo Campiciano as CFOPropanc Biopharma appoints Carlo Campiciano as CFO
seekingalpha.com - June 24 at 6:05 PM
Propanc Biopharma files for $10M equity offeringPropanc Biopharma files for $10M equity offering
seekingalpha.com - May 23 at 10:02 AM
Propanc Biopharma appoints Ralf Brandt to scientific advisory board as it develops cancer patentPropanc Biopharma appoints Ralf Brandt to scientific advisory board as it develops cancer patent
www.proactiveinvestors.com - May 15 at 10:06 AM
Propanc welcomes founding member back to scientific advisory boardPropanc welcomes founding member back to scientific advisory board
www.proactiveinvestors.com - May 6 at 5:37 PM
Propanc Biopharma Appoints Dr. Ralf Brandt to its Scientific Advisory BoardPropanc Biopharma Appoints Dr. Ralf Brandt to its Scientific Advisory Board
finance.yahoo.com - May 6 at 10:11 AM
Propanc looks to history to capitalize on glimmering angle in cancer treatmentPropanc looks to history to capitalize on glimmering angle in cancer treatment
www.proactiveinvestors.com - April 18 at 10:47 AM
Propanc Biopharma Initiates Development of Bio-Analytical Assay in Preparation for Human TrialsPropanc Biopharma Initiates Development of Bio-Analytical Assay in Preparation for Human Trials
finance.yahoo.com - March 25 at 10:03 AM
Propanc Biopharma IncPropanc Biopharma Inc
www.bloomberg.com - March 18 at 5:52 PM
Propanc Biopharma Receives Notice of Allowance for Additional Claims from Foundation Patent in the U.S.Propanc Biopharma Receives Notice of Allowance for Additional Claims from Foundation Patent in the U.S.
finance.yahoo.com - March 13 at 9:15 AM
Propanc Biopharma to Present at the 31st Annual ROTH Conference March 17 – 19, 2019Propanc Biopharma to Present at the 31st Annual ROTH Conference March 17 – 19, 2019
finance.yahoo.com - March 5 at 10:44 AM
Propanc Biopharma to Present at the 2019 BIO CEO & Investor ConferencePropanc Biopharma to Present at the 2019 BIO CEO & Investor Conference
finance.yahoo.com - January 29 at 10:06 AM
Propanc Biopharma Commences Drug Discovery Research CollaborationPropanc Biopharma Commences Drug Discovery Research Collaboration
finance.yahoo.com - January 2 at 9:47 AM
Propanc Biopharma’s Foundation Patent Granted in IndiaPropanc Biopharma’s Foundation Patent Granted in India
finance.yahoo.com - December 20 at 10:03 AM
Propanc Tags LHS to Get Word out, Shares PopPropanc Tags LHS to Get Word out, Shares Pop
www.baystreet.ca - December 18 at 4:22 PM
Propanc Biopharma Selects LaVoieHealthScience as Integrated Communications PartnerPropanc Biopharma Selects LaVoieHealthScience as Integrated Communications Partner
finance.yahoo.com - December 18 at 9:58 AM
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.